Drugs /

celecoxib

Back to Drugs List

Overview

NCI Definition [1]:
A nonsteroidal anti-inflammatory drug (NSAID) with a diaryl-substituted pyrazole structure. Celecoxib selectively inhibits cyclo-oxygenase-2 activity (COX-2); COX-2 inhibition may result in apoptosis and a reduction in tumor angiogenesis and metastasis.

Clinical Trials

View Clinical Trials for celecoxib

Celecoxib has been investigated in 16 clinical trials, of which 14 are open and 2 are closed. Of the trials investigating celecoxib, 1 is early phase 1 (1 open), 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 10 are phase 2 (9 open), and 1 is phase 3 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for celecoxib clinical trials.

Breast carcinoma, Ewing sarcoma, and atypical teratoid/rhabdoid tumor are the most common diseases being investigated in celecoxib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Celecoxib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Celecoxib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating celecoxib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
sc58635, celebrex, celecoxib product (product), celecoxib, ym 177, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide, celebrex, celecoxibum, p-(5-p-tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide, sc-58635, celebrex, 719627, celecoxib [chemical/ingredient], benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl]-, 169590-42-5, 58635, sc, celecoxib (substance), celecoxib, celecoxib product, célécoxib, sc 58635
Drug Target(s) [2]:
PTGS2
NCIT ID [1]:
C1728
SNOMED ID [1]:
C-6031A

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.